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Histone acetylation is a posttranslational modiﬁcation that plays a role in regulating gene expression. More recently, other
nonhistone proteins have been identiﬁed to be acetylated which can regulate their function, stability, localization, or interaction
with other molecules. Modulating acetylation with histone deacetylase inhibitors (HDACi) has been validated to have anticancer
eﬀects in preclinical and clinical cancer models. This has led to development and approval of the ﬁrst HDACi, vorinostat, for
the treatment of cutaneous T cell lymphoma. However, to date, targeting acetylation with HDACi as a monotherapy has shown
modest activity against other cancers. To improve their eﬃcacy, HDACi have been paired with other antitumor agents. Here, we
discuss several combination therapies, highlighting various epigenetic drugs, ROS-generating agents, proteasome inhibitors, and
DNA-damaging compounds that together may provide a therapeutic advantage over single-agent strategies.
1.Introduction
Overtime,anappreciationoftheimportanceandcomplexity
of epigenetic events, such as DNA methylation, histone
posttranslational modiﬁcations, and miRNA regulation, has
fueled interest in many new areas of research. Histone acet-
ylation is one process that is being intensely studied due to
its ability to regulate gene transcription. The enzymes that
regulate histone acetylation are often inappropriately ex-
pressed in cancer cells, which can lead to the silencing of
tumor suppressor genes or activation of oncogenes. Because
of this, many of these enzymes have become popular
targets for cancer therapy. In this paper we will highlight
histone deacetylase inhibitors, a group of compounds that
blocks the zinc-dependent histone deacetylases involved in
removing acetyl groups from lysine residues. Modulation
of protein acetylation by the ﬁrst-in-class FDA (U S Food
and Drug Administration) approved HDACi, vorinostat, has
been shown to be successful for the treatment of refractory
cutaneous T cell lymphoma (CTCL). However, despite the
promising results employing HDACi as an epigenetic tar-
geted therapy, its limited success in speciﬁc cancers as a
single drug has prompted further investigation of combining
HDACi with other anticancer agents. These combination
regimens, which will be the focus of this review, may
enhance the clinical eﬃcacy of HDACi and may provide a
therapeutic advantage in cancers where HDACi alone have
limited activity.
2. HistoneDeacetylases(HDACs)andCancer
Histone deacetylases (HDACs) are a group of enzymes that,
in conjunction with histone acetyltransferases (HATs), reg-
ulate the acetylation status of histone tails. HATs acetylate
lysine residues on histone tails resulting in neutralization
of their charge and decreased aﬃnity for DNA [1]. This2 Journal of Biomedicine and Biotechnology
“loosening” of the histone-DNA interaction is associated
with conformational changes which allow for transcription
factors to bind to the DNA and impact gene transcription
[2]. HDACs, on the other hand, remove acetyl groups which
lead to a more compact chromatin conformation that is
often associated with gene repression. Importantly, HDACs
usually do not function alone, but are part of multiprotein
complexes that contain DNA-binding proteins, chromatin-
remodeling proteins, and other histone-modifying proteins
that participate together to regulate transcription. In addi-
tion, according to the “histone code” hypothesis, histone
modiﬁcations work together with other epigenetic modiﬁ-
cations to determine certain transcriptional outcomes [3].
HDACs are categorized into four families, class I, II, III,
and IV, based on their structure. Class I, which includes
HDAC 1, 2, 3, and 8, is predominately localized to the
nucleus. Class II consists of HDACs 4, 5, 6, 7, 9, and 10 and
is detected in both the nucleus and cytoplasm. HDAC 11
is the sole class IV member and resides in the nucleus [4].
These three classes of HDACs are zinc-dependent enzymes
and are the molecular targets of HDACi. In contrast, class
III is comprised of the NAD-dependent deacetylases, sirtuins
(SIRT 1–7), which are found in the nucleus, cytoplasm,
and mitochondria and have been identiﬁed to be involved
in metabolism and aging [5]. However, they will not be
discussed in this paper since they are not targets of HDACi.
There are numerous studies demonstrating that histones
are not the only substrates for HDACs and HATs. These en-
zymes also regulate acetylation of nonhistone proteins,
including transcription factors, chaperone proteins, and sig-
naling molecules involved in cancer development and pro-
gression such as the tumor suppressor p53 [6]. In general,
acetylation can interfere with binding, function, and/or
stability (turnover) of the protein. Since HDACs are involved
in deacetylating a wide variety of substrates they have been
identiﬁed to modulate many cellular processes and thus may
be used by cancer cells for a survival advantage. Based on
this rationale, eﬀorts to deﬁne which HDACs are involved in
cancer development and progression are being undertaken.
Many of these studies have employed HDACi to demonstrate
the validity of HDACs as therapeutic targets, but eﬀects
were selective to cancer type or were inhibitor speciﬁc.
However, strategies using small interfering RNA (siRNA)
against class I and II HDACs have been used to determine
which HDACs play a role in proliferation and survival of
cancer cells. Silencing of HDAC 1 and 3 by siRNA resulted
in antiproliferative eﬀects in human cervical carcinoma cells
(HeLa) [7]. However, silencing class II HDACs, HDAC 4 and
7, did not have an eﬀect on proliferation [7]. Additionally,
HDAC 3 knockdown by siRNA resulted in hyperacetylation
of histone-H3 and an increase in apoptotic cell death [7].
These results suggest that, at least in the case of cervical
carcinoma, class I HDACs may be better candidates for
inhibition over class II isoforms. Yet, it is diﬃcult to pin-
point which HDACs are suitable targets since examination
of HDAC expression levels diﬀers greatly from cancer to
cancer, with many displaying aberrant levels. In some cases,
even the surrounding normal tissue may also express high
levelsofHDACs,beggingthequestionofhowonlymalignant
cells can be targeted with HDACi and not healthy cells.
Surprisingly, studies show that HDACi selectively target
tumorcellsatdoses thathave very little eﬀectonnormalcells
[8–10]. This susceptibility of transformed cells to HDACi
therapy is probably due to their dependence on HDACs
for modulating expression of genes involved in tumor cell
growth, diﬀerentiation, and apoptosis that provide cancer
cells with a survival advantage (further discussed Section 4)
[11]. Because of this reliance, interfering with HDACs for a
therapeutic advantage in cancer is gaining momentum.
3.Development of HistoneDeacetylase
Inhibitors (HDACi) for Cancer Therapy
Initially, HDACi were identiﬁed by several groups as agents
that induced diﬀerentiation of murine erythroleukemia cells
(MELC). Transfection experiments in MELC performed by
Friend et al. revealed that treatment with dimethyl sul-
foxide (DMSO) resulted in synthesis and accumulation of
hemoglobin, an indication of erythroid diﬀerentiation [12].
Similar results were also observed by Yoshida et al. in exper-
iments that demonstrated diﬀerentiation of MELC with a
naturally derived antifungal antibiotic, trichostatin A (TSA)
[13]. Further analysis of TSA in rat ﬁbroblasts showed that
this compound induced G1 and G2 cellcyclearrest but, most
importantly, subsequent studies analyzing histone modiﬁca-
tions identiﬁed histone deacetylases as the molecular targets
for TSA. During this time, Paul Marks’ group discovered
that HMBA, a small molecule polar compound, was able to
induce diﬀerentiation similarly to DMSO [14]. Compounds
that share certain structural features with DMSO have now
been synthesized in an attempt to generate compounds with
increased anticancer eﬃcacy [15]. One of these compounds
is suberoylanilide hydroxamic acid (SAHA), now known
as vorinostat. However, the targets of these diﬀerentiating
compounds were still unknown until closer examination of
the structure of vorinostat revealed a similarity to the struc-
ture of TSA. Based on these observations, Marks’ group
reported in 1998 that vorinostat targeted HDACs, inhibiting
HDAC 1 and 3 resulting in acetylation of histones in various
cancer cell lines [15]. Subsequent studies over the next eight
years demonstrated that vorinostat modulated transcription
of gene expression and had antitumor selectivity in in vivo
cancermodels.Eventually,thisledtoitsevaluationinclinical
trials and the FDA approval of the ﬁrst-in-class HDACi for
cancer treatment.
Since these events, several HDACi have been identiﬁed
either through synthetic or natural sources. HDACi can be
separated into several structurally distinct classes: short-
chain fatty acids (i.e., valproic acid), hydroxamic acids (i.e.,
vorinostat, TSA, and PCI-24781), benzamides (i.e., entinos-
tat),cyclictetrapeptides(i.e.,depsipeptide),andelectrophilic
ketones. Some of these compounds selectively block speciﬁc
classes of HDACs, while some have a broader spectrum of
activity and therefore inhibit several classes of HDACs. For
example, the benzamide entinostat (previously known as
SNDX-275 or MS-275) is selective for class I HDACs (HDAC
1, 2, and 3), while the HDACi tubacin speciﬁcally targetsJournal of Biomedicine and Biotechnology 3
only HDAC 6 [16]. In contrast, the majority of hydroxamic
acids, including vorinostat, panobinostat (LBH589), and
TSA, behave as pan-HDACi, blocking several classes of
HDACs, although more selective hydroxamic acid inhibitors
are being developed. For example, a novel hydroxamic acid,
PCI-24781,iscurrentlyinphaseIclinicaltrials,preferentially
inhibits class I and II HDACs, and is more potent at targeting
these isoforms compared to vorinostat [17].
4. HDACi:Mechanisms of Action
Treatment with HDACi has been found to change the gene
expression of about 7% of the genes studied, indicating that
HDACi can be used to alter a subset of genes [18]. In fact,
gene expression analyses have demonstrated that HDACi can
selectively induce apoptosis in cancer cells by upregulating
and/or downregulating the expression of proapoptotic and
antiapoptotic genes [19]. Mechanistic studies have impli-
cated activation of the death-receptor (extrinsic) pathway or
the mitochondrial (intrinsic) apoptotic pathways as a mech-
anism of action of diﬀerent HDACi. Induction of distinct
cell death pathways may be associated with the structurally
diverse HDACi, which have diﬀerent targets and have been
demonstrated to be cell-type dependent.
The role of HDACi in triggering the extrinsic apoptotic
pathway has been demonstrated by several in vitro studies.
In these experiments, HDACi have shown to activate death
receptors, including TRAIL, DR5, FAS, and TNF alpha [19].
These observations have been validated by studies where the
inhibition of death receptors and their ligands abrogated
HDACi-dependent apoptosis [10, 20]. In addition, in vivo
experiments suppressing TRAIL and Fas by siRNA in mice
resulted in a signiﬁcant reduction in apoptosis after treat-
ment with the HDACi, valproic acid [21]. Yet, several studies
havealsoimplicatedtheinvolvementoftheintrinsicpathway
in HDACi-induced apoptosis. HDACi can transcriptionally
regulate the expression of proapoptotic BH3-only proteins
including Bid, Bad, and Bim, which play an important role
in the activation of the intrinsic apoptotic pathway [22–24].
Furthermore,elevatedlevelsofreactiveoxygenspecies(ROS)
have been observed after treatment with HDACi [24–26].
The increase in ROS has been shown to precede changes in
mitochondrial membrane potential [27], suggesting a link
between HDACi, ROS, BH3—only proteins and activation
of the intrinsic pathway.
In fact, oxidative stress has been identiﬁed as a mecha-
nism by which HDACi may be exerting its lethal eﬀects in
tumor cells. However, the manner by which HDACi induce
oxidative stress is not well understood. Two prominent
mechanisms have been reported. One involves mitochon-
drial injury, while the other implicates modulating antioxi-
dants levels (Figure 1). In an acute leukemia treated cell line,
vorinostat induced apoptosis by the expression of proapop-
totic Bid, which resulted in disruption of mitochondria, a
major source of ROS in the cell. Accordingly, subsequent
production of ROS was observed in these cells (Figure 1(a))
[24]. More recently, detailed studies by Paul Marks’ labora-
toryhavedemonstratedthatvorinostatandentinostatupreg-
ulate thioredoxin binding protein-2 (TBP-2), which is a pro-
tein that binds and inhibits thioredoxin (Trx) (Figure 1(b))
[28]. Trx is a ubiquitous protein with pleiotropic eﬀects,
with one of its major functions to operate as an intracellular
antioxidant. Interestingly, studies have shown that this
antioxidant is upregulated in certain types of tumors [29, 30]
perhaps giving cancer cells a survival advantage to deal with
the elevated oxidative stress. These ﬁndings indicate that Trx
maybeagoodcandidatetotargetforthetreatmentofcancer.
Ungerstedt and colleagues demonstrated that exposure of
transformed cells to HDACi resulted in ROS-dependent
apoptosis. Furthermore, nontransformed cells were resistant
to this HDACi treatment; instead an increase in Trx levels
was detected, and no production of ROS was observed. The
rise of HDACi-induced Trx expression in nonmalignant cells
oﬀered cytoprotection since siRNA against the antioxidant
resulted in increased oxidative stress and sensitivity towards
HDACi [9]. These observations of Trx overexpression oﬀer-
ing a protective mechanism against HDACi provides an
additional explanation of the selectivity of HDACi for some
cancer cells compared to nontransformed cells.
HDACi have also been shown to induce cell cycle arrest.
The mechanism by which HDACi induce cell cycle arrest
includestheinductionofcellcyclegeneslikeCDKN1Awhich
encode the production of p21WAF1/CIP1 [22, 31]. Also, HDACi
can transcriptionally repress cyclin D and cyclin A genes
resulting in the loss of CDK2 and CDK4 kinase activity
[32, 33]. In addition to the induction of apoptosis and cell
cycle arrest, HDACi have been shown to have antiangiogenic
eﬀects by downregulating proangiogenic genes like vascular
endothelial growth factor (VEGF) and endothelial nitric
oxide synthase (eNOS) [34]. These antiangiogenic eﬀects
have been observed in diﬀerent cancer models both in vitro
and in vivo [34–36]. These studies support the possibility
of HDACi interfering with the metastatic process. However,
more studies are needed to understand better their role in
metastasis.
5.HDACiinthe Clinic
PreclinicalstudiesofHDACi,incelllinesandanimalmodels,
have proven to be very successful as single-modality agents
for the treatment of a variety of cancers. As a result, several
structurally diﬀerent HDACi have been used in hundreds of
clinical trials to test their toxicity and eﬃcacy. In general,
clinicaltrialsinvolvingHDACialone,orincombinationwith
other chemotherapeutic agents, yield promising results and
demonstrate biological and antitumor activity.
Vorinostat is the ﬁrst HDACi to show promise in the
clinic. In phase I and II trials, vorinostat was well tolerated
and ∼30% of CTCL patients enrolled in the study received
clinical beneﬁt [37]. However, in other phase II trials eval-
uating the eﬃcacy of vorinostat in solid tumors, including
ovarian [38], breast, colorectal, nonsmall cell lung [39], head
and neck [40], and glioblastoma [41], only a moderate eﬀect
was observed. Moreover, treatment of metastatic tumors
with vorinostat had limited success [40, 42, 43].4 Journal of Biomedicine and Biotechnology
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Figure 1: Proposed mechanisms by which HDACi induce ROS. (a) Mitochondrial injury. HDACi induces expression of Bid protein.
This proapoptotic molecule binds to and disrupts the mitochondrial membrane, which results in increased ROS levels and apoptosis. (b)
Alterations in antioxidant levels. HDACi upregulate the expression of thioredoxin-binding protein-2 (TBP-2). TBP-2 binds to and inhibits
theantioxidantthioredoxin(Trx).ThisinhibitionresultsinanimbalanceofoxidantsandantioxidantsleadingtoincreasedROSlevels,which
promotes apoptosis.
Upon the success of vorinostat in CTCL and its approval
by the FDA for this disease, several new HDACi were devel-
opedandhavebeeninvestigatedinclinicaltrials(reviewedin
[44]).Therearecurrentlycloseto50activeclinicaltrialseval-
uating several HDACi as monotherapies for a variety of can-
cers and over 100 trials combining HDACi with other che-
motherapeutic agents (http://www.clinicaltrials.gov/, http://
www.cancer.gov/clinicaltrials). These studies include pan-
HDACi, such as the novel compound PCI-24781 (Pharma-
cyclics), as well as isoform-speciﬁc HDACi, such as entin-
ostat. Preclinical studies using PCI-24781 demonstrate an
inhibition in cell growth and an increase in apoptosis, and
treatment of colon tumor xenografts signiﬁcantly reduces
tumor volume [17]. PCI-24781 is currently under evaluation
in phase I trials for sarcoma, non-Hodgkin lymphoma, mul-
tiple myeloma, and chronic lymphocytic leukemia. Another
structurally diﬀerent HDACi, entinostat, is more selective
for class I HDACs. Like vorinostat, entinostat shows the
greatest therapeutic response in patients with leukemia and
lymphoma[45,46]whereasitisonlymoderatelyeﬀectivefor
solid tumors [47, 48]. Entinostat is currently being evaluated
as mono- and combination therapies for a variety of cancer
types (Table 1).
Despite promising preclinical in vitro and in vivo data
evaluating HDACi, clinical trials using these agents as
monotherapieshavemostlybeensuccessfulintreatingCTCL
and hematological malignancies. One explanation for this
observation is the inability to achieve appropriate doses of
HDACi and consistent acetylation of target proteins. In
vitro studies evaluating HDACi require at least 24 hours
and micromolar concentrations to cause tumor cell death.
Phase I clinical trials of vorinostat demonstrate that plasma
concentrations (Cmax) reach the micromolar range, 2.5μM
for oral administration of 400mg/d and 9μM for 300mg/m2
per day for intravenous administration [49]; however the
half life is relatively short, 91.6–127 minutes orally and 34.7–
42.4minutesintravenously[50].Thesedatasuggestthatcon-
tinuous administration of these agents may be necessary to
achieve clinical response. This may not be feasible with a
broad-spectrum HDACi, like vorinostat, due to the large
numberofacetylatedtargetproteinswhichmaycontributeto
dose-limiting toxicities. HDACi clinical trials primarily focus
on evaluating the acetylation status of histone H3 and H4
to determine whether these compounds are blocking their
substrates. These pharmacodynamic studies have revealed
that increased acetylation of histone H3 and H4 is observed
inperipheralbloodmononuclearcells(PMBCs)and/orbone
marrow mononuclear cells (BMMCs) of patients treated
with HDACi, indicating that these inhibitors are targeting
HDACs. However, similar increased acetylation has been
detected in both responders and nonresponders suggesting
that increased histone acetylation in PMBCs and BMMCsJournal of Biomedicine and Biotechnology 5
Table 1: HDACi combination regimens currently in clinical trials. Partial list of clinical trials evaluating the combination of HDACi with
other anticancer agents discussed in this paper (source: http://www.clinicaltrials.gov/, http://www.cancer.gov/clincialtrials).
HDACi Other Intervention Tumor Type
Entinostat (SNDX-275) azacitidine leukemia, MDS, colorectal cancer, NSCLC
Mocetinostat (MGCD0103) azacitidine MDS
Panobinostat (LBH589)
azacitidine MDS, CML, AML
bortezomib peripheral T cell lymphoma, NK/T cell
lymphoma, MM, pancreatic cancer
bortezomib, dexamethasone MM
decitabine MDS, AML
decitabine, temozolomide melanoma
radiation therapy prostate cancer, esophageal cancer, head and neck
cancer
PCI-24781 doxorubicin sarcoma
Romidepsin bortezomib myeloma
Valproic acid
azacitidine advanced cancers
azacitidine, ATRA AML, MDS
decitabine, ATRA AML
radiation therapy, bevacizumab children with high grade gliomas
radiation therapy, temozolomide high grade gliomas, brain tumors
Vorinostat
azacitidine AML, MDS, DLBCL, lymphoma, MM, NSCLC,
Non-Hodgkin’s lymphoma
bortezomib, AMG 655 lymphoma
bortezomib, dexamethasone MM
cisplatin, pemetrexed, radiation
therapy NSCLC
cisplatin, radiation therapy squamous cell carcinoma
gemtuzumab ozogamicin, azacitidine AML
marizomib (NPI-0052) NSCLC, pancreatic cancer, melanoma, lymphoma
paclitaxel, radiation therapy NSCLC
radiation therapy brain metastases, NSCLC, pancreatic cancer,
pelvic cancer
radiation therapy, ﬂuorouracil pancreatic adenocarcinoma
ATRA: all-trans retinoic acid, MM: multiple myeloma, NSCLC: nonsmall cell lung carcinoma, AML: acute myeloid leukemia, CML: chronic myelogenous
leukemia, MDS: myelodysplastic syndrome, and DLBCL: Diﬀuse large B-cell lymphoma.
doesnotcorrelatewithclinicalresponse.Histonesarenotthe
only proteins capable of being acetylated. Our knowledge of
acetylated nonhistone proteins is rapidly increasing through
eﬀorts to deﬁne the acetylome [51] but the biological rele-
vance of acetylation on many of these proteins is still mostly
unknown. A greater understanding of the acetylome may
revealother molecularendpoints thatmight indicate a favor-
able clinical response or that might identify contributors of
dose-limiting toxicities. Inaddition, deciphering theindivid-
ual role of each individual HDAC in cancer progression will
aid in knowing which speciﬁc isoform to target. However,
even isoform-speciﬁc inhibitors may not completely elimi-
nate on-target dose-limiting toxicities because most HDACs
reside in multiple large multiprotein complexes. A single
HDAC can simultaneously play diﬀerent roles within the cell
depending on which complex it is associated. In addition
to the speciﬁcity of HDACi, the lack of response of some
patients to HDACi therapy may be attributed to mechanisms
of resistance [50].
Overall, HDACi have shown promise in the clinic but
there is clearly room for improvement of therapeutic index.
One way to achieve greater clinical eﬃcacy is to use HDACi
in combination with other chemotherapeutic agents. In
fact, many preclinical studies provide evidence supporting
synergistic or additive eﬀects of HDACi in combination
with other cytotoxic agents, and a partial list of HDACi
combination trials is found in Table 1. The agents listed will
be the focus of the remainder of the paper.
6.Combining HDACiwithOther
Epigenetic Therapies
The predominant function of HDACs is the modiﬁcation of
histone tails which inﬂuences gene transcription. In addition6 Journal of Biomedicine and Biotechnology
tohistoneacetylation,genetranscriptionisalsocontrolledby
DNA methylation and histone methylation. These processes
often work in concert with one another providing the ration-
ale for combining epigenetic therapies for cancer treatment.
6.1. DNA Methyltransferases. DNA methylation involves the
covalent addition of a methyl group to cytosine residues
of DNA by enzymes termed DNA methyltransferases
(DNMTs). Often, DNA methylation occurs within CpG
islands located within the 5  promoter regions of genes [52].
DNA methylation can inhibit transcription directly by inﬂu-
encing transcription factor binding [53] but also maintains
chromatin in a transcriptionally inactive state through the
recruitment of methyl-CpG binding proteins (MBDs) [54,
55], some of which recruit histone deacetylases for added
epigenetic control [56, 57]. In normal cells, the CpG islands
of transcriptionally active genes are not methylated [52].
However, in cancer, many of the unmethylated genes become
aberrantly methylated [58–60]. The discovery that CpG
methylation was a causative event in tumor progression
led to the search for drugs which could reverse the DNA
methylation and restore gene expression.
The ﬁrst-FDA approved DNMT inhibitors (DNMTi) are
thenucleoside analogs5-azacytidine (azacitidine) and5-aza-
2 -deoxycytidine (decitabine). Nucleoside analogs, as well
as nonnucleoside analog DNMTi, are eﬀective anticancer
agents that cause increased apoptosis [61]. Moreover, these
agents reverse the DNA hypermethylation association with
certain cancer genes and alter gene expression [61–63].
However, there is a wide variation among the diﬀerent
agents which led to the hypothesis that DNA methylation
inﬂuences the stability of other chromatin marks prompting
the evaluation of combined use of DNMTi and HDACi [64].
Several preclinical studies evaluating the eﬀects of
DNMTi in combination with HDACi demonstrate syner-
gistic anticancer activity. For example, cotreatment of pros-
tate cancer cells [65]o rp a n c r e a t i cc a n c e rc e l l s[ 66]w i t h
decitabine and TSA led to reduced cell proliferation which
was accompanied by increased apoptosis. Similar results
were obtained in other cell lines where enhanced apoptosis
w a so b s e r v e di nA M L 1 / E T O - p o s i t i v ea c u t em y e l o g e n o u s
leukemia (AML) cells [67] and decreased cell proliferation
was observed in lung cancer cells [68] treated with depsipep-
tideanddecitabine.Moreover,entinostatandazacitidinedis-
play synergistic cytotoxicity and apoptosis in leukemia cells
which correlates with enhanced rates of histone acetylation
as well as elevated intracellular reactive oxygen species [26].
Given the promising preclinical data combining HDACi with
DNMTi, several clinical trials utilizing the combination were
administered to patients with hematologic and solid tumors
where many of the patients had minimal side eﬀects and
some achieved complete and partial remissions [69, 70].
Currently, there are 14 trials evaluating DNMTi with HDACi
(Table 1).
6.2. Histone Demethylases. The methylation status of histo-
nes also plays an important role in gene expression. Al-
though, for many years, histone methylation was considered
tobeastable,irreversiblemodiﬁcation, recently,twofamilies
of enzymes have been discovered which function to remove
methyl groups from the lysines of histone and nonhistone
proteins. The ﬁrst enzyme to be discovered was the lysine-
speciﬁc demethylase 1 (LSD1) which functions similar to the
amine oxidase family of enzymes [71]. The second family
of enzymes discovered are the jumonji-domain-containing
proteins[72].Thesemetalloenzymesmediatehydroxylation-
based demethylation of lysines [72]. Both of these families
of demethylase enzymes have been reported to reside in
complexes containing HDACs [73, 74], and the activity of
LSD1 is inﬂuenced by HDAC function [74], providing the
rationale for targeting both enzymes as epigenetic therapy.
Due to the structural similarity between LSD1 and
the amine oxidase family of enzymes, several groups have
demonstrated that mono- and polyamine oxidase inhibitors
also target LSD1 [74–79]. Studies from our laboratory evalu-
ating cotreatmentof glioblastoma cellswiththe combination
ofHDACi,vorinostatorPCI-24781,withtheLSD1inhibitor,
tranylcypromine,showasynergisticincreaseinapoptoticcell
death[80]. Moreover, treatment of normal human astrocytes
with the same doses of HDACi and tranylcypromine did
not yield enhanced cell death suggesting that the synergis-
tic apoptosis induced by the combination is selective for
glioblastomacells[80].ThesedatasupporttheuseofHDACi
and LSD1 as combination therapy in preclinical mouse
studies. In addition, future studies aimed at understanding
the molecular mechanisms by which HDACs and LSD1
regulate cancer cell growth have the potential to identify new
molecular targets for therapy.
Not only there is cross-talk between LSD1 and HDACs,
but also LSD1 is required for the maintenance of global DNA
methylation [81]. Moreover, LSD2, a homolog of LSD1, par-
ticipates in establishing maternal genomic imprints during
oogenesis [82]. These data suggest that targeting the LSD
family and DNMTs may enhance the antitumor activity of
these drugs. In fact, inhibition of LSD1 in human colorectal
cells with a combination of novel oligoamine analogs and
DNMTi led to a greater re-expression of aberrantly silenced
genes when compared to either agent used alone [83]. In
addition, colorectal xenograft models treated with the com-
bination of PG-11144, an oligoamine analog inhibitor, and
azacitidine caused dramatic decreases in tumor cell growth
demonstrating the therapeutic eﬃcacy of this combination
[83].
The discovery of lysine demethylases and the inﬂuence
these enzymes have on many biological processes has led to
the recognition of their potential as a therapeutic target
in a variety of diseases, including cancer. Developing more
speciﬁc inhibitors for the demethylase enzymes, particularly
the jumonji-domain-containing family where investigators
are just now starting to identify inhibitors [84], will aid
in understanding what role individual demethylases play
during cell growth and development. These studies will
make substantial contributions to our knowledge regarding
epigenetic regulators and are needed to utilize epigenetic
therapies to their fullest potential.Journal of Biomedicine and Biotechnology 7
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Figure 2: Activation of apoptosis by combinations of HDACi
and ROS-generating agents. HDACi combined with agents like
adaphostin and PEITC result in an increase production of ROS in
cancer cells. The high levels of ROS result in induction of apoptosis
via caspase activation.
7. HDACiandROS-GeneratingAgents
Several reports have shown that HDACi induce oxidative
stress in diﬀerent types of cancer cells [85]. Cancer cells also
havehigherlevelsofreactiveoxygenspecies(ROS)compared
to normal cells, most likely as a consequence of an active
metabolism and more robust proliferation rates [86, 87].
Thisdiﬀerencehasbeenusedasatherapeuticstrategytotreat
cancer. Combining HDACi with agents that cause further
oxidative stress might enhance the eﬃcacy of HDACi for the
treatment of cancer (Figure 2).
7.1. Adaphostin. Adaphostin is a drug that is part of the tyr-
phostin family of tyrosine kinase inhibitors, and it aﬀects
an u m b e ro fd i ﬀerent kinases. It is an analog of AG957,
a drug that was originally developed to inhibit p210Bcr/abl
[88]. However, studies have demonstrated that adaphostin’s
activity is not restricted by the presence or absence of
Bcr/Abl kinase [89]. This compound has been identiﬁed as
a potential anticancer agent to treat acute leukemias such as
AML and ALL (acute lymphoblastic leukemia). Importantly,
adaphostin demonstrates selectivity for leukemia cells as
compared to normal lymphocytes [85]. Mechanistic studies
have demonstrated that adaphostin elevates levels of intra-
cellular ROS, resulting in apoptosis [90]. Additional inves-
tigations by Le et al. expand these observations by showing
that the increase in ROS in cells treated with adaphostin is
the result of its accumulation in the mitochondria, where
adaphostin binds to complex III, inhibiting electron trans-
port [91] and leading to oxidative stress. Moreover, tran-
scriptional and proteomic analyses of adaphostin-treated
cellsdemonstratedanupregulationofoxidativestress-related
genes and antioxidants [92], including the genes encoding
heat shock proteins, glutathione S-transferase (GST), and
superoxide dismutase. A decrease in the antioxidant gluta-
thione has also been observed in studies in CML (chronic
myelogenous leukemia) cells treated with adaphostin [90].
Takentogether,theseobservationsindicatethatadaphostinis
a redox-modulatory agent and a good candidate to combine
with HDACi.
Unpublished data from our group shows strong synergy
between two structurally diﬀerent HDACi (entinostat and
vorinostat) and adaphostin resulting in apoptosis in leuke-
mia cells. Results showed a threefold increase in DNA frag-
mentation, a hallmark of apoptosis, when cells were treat-
ed with adaphostin combined with entinostat compared to
cells treated with HDACi alone. A more potent eﬀect was
achieved with adaphostin and vorinostat, demonstrating a
sixfold increase in DNA fragmentation. Furthermore, these
combinations enhanced superoxide levels, suggesting that
oxidative stress plays a role in the synergistic induction of
apoptosis.Theresultsobservedwiththesecombinationslend
support to the idea of enhancing the eﬃcacy of HDACi by
modulatingROSlevelswithanoxidant-generatingagentthat
may push the balance towards oxidative stress and cell death
andprovideatherapeuticadvantageforthetreatmentofcan-
cers such as leukemia.
7.2. β-Phenylethyl Isothiocyanate (PEITC). A second redox-
modulatory agent, which has shown promises for the treat-
ment and prevention of cancer, is PEITC. This agent is
a natural compound found in cruciferous vegetables like
cauliﬂower, broccoli, and cabbage. PEITC has been shown to
be eﬀective in cancer cells by inhibiting carcinogenesis and
inducing cell growth arrest and apoptosis [93]. Studies in
prostate cancer cells demonstrate that PEITC induce apop-
tosis by decreasing the levels of the antiapoptotic proteins
Bcl-2 and Bcl-XL [94]. In addition, it has been shown to
downregulate and facilitate the degradation of the andro-
gen receptor [95]. More detailed mechanistic studies have
revealed the main mechanism by which PEITC works as an
anticancer agent is through redox-modulating mechanisms.
These mechanisms include the inhibition of cytochrome
P450 and the induction of metabolizing enzymes like
NAD(P)H:quinoneoxidoreductase(NQO-1)andGST[93].
Am o r er e c e n ts t u d yr e p o r t sp r o d u c t i o no fR O Sb yP E I T C
to be mediated by inhibition of complex III and oxidative
phosphorylation[96].Inaddition,invitroandinvivostudies
have demonstrated PEITC to induce an accumulation in
ROS that is mediated by the depletion of the antioxidant,
glutathione (GSH) [97]. Furthermore, the increase of ROS
and depletion of GSH by this agent have been shown to
overcome the resistance of leukemia cells to ﬂudarabine [98].
Taking into consideration that PEITC is a ROS modu-
lating agent, it can perhaps be combined with HDACi to
improve its eﬃcacy. Recently, Hu et al. addressed this as-
sumptionanddemonstratedthatdepletionofGSHbyPEITC
increases sensitivity to vorinostat in leukemia cells. Further-
more, the combination of HDACi/PEITC also induced ROS
accumulation and apoptosis in a vorinostat-resistant cell line
via activation of the NADPH oxidase. Induction of ROS by
thiscombinationallowsforthetranslocationoftranscription8 Journal of Biomedicine and Biotechnology
factor Nrf2 to the nucleus, stimulating transcription of genes
involved in the glutathione system [99].
All together, these studies suggest that the regulation of
oxidative stress plays an important role in the cytotoxic ef-
fects with HDACi and ROS generating agents. Further
understanding how HDACi, alone or in combination with
other redox-modulating agents, regulate oxidative stress will
help in the development of better therapeutic strategies for
clinical utility. Presently there are multiple clinical trials
combining HDACi with other chemotherapies that together
have been demonstrated to increase ROS. Some of these
agents include proteasome inhibitors and DNA-damaging
agents. The combination of HDACi with these agents will be
discussed in the next two sections.
8. Proteasome InhibitorsandHDACiRegimens
A growing body of work in the literature is providing evi-
dence to support the use of proteasome inhibitors as an op-
tion to combine with HDACi. The molecular targets of these
compounds are the enzymatic activities housed within the
proteolytic chamber of the proteasome. These include the
chymotrypsin-, caspase-, and trypsin-like proteolytic activ-
ities that are responsible for degrading the majority of intra-
cellular proteins [100]. Thus, inhibiting the proteasome will
inﬂuence many signaling pathways and cellular processes,
including cell growth and survival, tumor suppression, and
apoptosis. Surprisingly, most likely due to their rapid protein
turnover rate, cancer cells rely heavily on the proteasome
to dispose of unwanted proteins and therefore are more
susceptible to proteasome inhibition compared to nontrans-
formedcells [101, 102]. One of the most commonly reported
consequences of proteasome inhibition in tumor cells is
cell death. As a result of this selectivity, similar to HDACi,
compounds that target the proteasome have emerged as
novel cancer therapies in the recent years. However, despite
the promise of both HDACi and proteasome inhibitors
in preclinical and in vivo models as single agents, similar
responses have not been duplicated in clinical settings. One
way to overcome these unexpected shortcomings has been
to combine these two diﬀerent compounds to enhance
their antitumor activity. Speciﬁcally, three clinically relevant
proteasome inhibitors—bortezomib, marizomib (formerly
known as NPI-0052), and carﬁlzomib—are proving to be
strong candidates for combination regimens with HDACi.
8.1. Bortezomib. Originally synthesized as an inhibitor of the
chymotrypsin-like activity of the proteasome, the boronic
acid-derived compound bortezomib is the sole FDA-ap-
proved drug of its class for multiple myeloma (MM) and
mantle cell lymphoma (MCL). This reversible inhibitor has
been shown to work in combination with HDACi by induc-
ing cytotoxic eﬀects mediated primarily by cellular stress,
JNK(JunNH2-terminalkinase)activation,andupregulation
of proapoptotic proteins. Stress to the cell is a commonly
characterized event produced by the combination treatment
that triggers apoptosis in cancer cells, and two major
sources of stress stand out (Figure 3). The ﬁrst one involves
the generation of reactive oxygen species. Pretreatment with
bortezomib sensitized MM cells to two diﬀerent HDACi,
vorinostat and sodium butyrate, inducing synergistic apop-
tosis [103]. Mitochondrial injury, JNK activation, caspase
activation, and increased oxidative stress were among the
events observed with the combination regimen. Important-
ly, treatment with an antioxidant markedly decreased JNK
activation and apoptosis suggesting that ROS was contribut-
ing to these eﬀects [103]. Similar ROS-dependent apoptosis
was also observed in Bcr/Abl+ leukemic cells with the same
combination treatment. Moreover, cell death was induced
by bortezomib/HDACi in Gleevec-resistant K562 (Bcr/Abl+
CML) cells and patient-derived CD134+ cells that were
refractory to Gleevec therapy [104]. These ﬁndings indi-
cate that this proteasome inhibitor/HDACi regimen may
provide beneﬁts in cancers that have acquired resistance to
their current therapies. Cytotoxic oxidative stress and DNA
damage have also been reported in MM cells when borte-
zomib was paired with another HDACi, PXD101 [105].
Bhalla et al. report greater lethality in lymphoma cells
when bortezomib was combined with PCI-24781 compared
to single-agent treatment. The cell death observed in this
m o d e ls y s t e mw a sa l s oR O Sd e p e n d e n t[ 106]. Furthermore,
gene expression analyses revealed downregulation of antiox-
idant genes with PCI-24781, and these eﬀects were further
enhanced when combined with bortezomib [106]. These
results hint at a process by which oxidative stress may be
altered when pairing HDACi with bortezomib. However, the
source of ROS when these molecular-targeted therapies are
combined is not completely clear. For proteasome inhibitors
as single agents, studies in nonsmall cell lung cancer using
peptide inhibitors seem to suggest that the mitochondrial
electron transport chain is involved in producing oxidative
stress [107]. However, these observations do not rule out
involvement of other ROS-generating systems and do not
reveal if it is speciﬁc to particular cancer types. For HDACi,
inhibitionoftheantioxidantthioredoxinhasbeenimplicated
for production of ROS by HDACi [28]. Further examination
into the interaction between proteasome inhibitors and
HDACi may reveal additional mechanisms at play, similar to
those observed by Bhalla et al. in their lymphoma studies.
The other relevant mechanism that is thought to be
important in the synergistic eﬀects between these two agents
is disruption of aggresome formation. Work by Nawrocki
et al. showed that bortezomib induced ubiquitin-conjugated
protein aggregates, which appeared to provide a protec-
tive mechanism to cells exposed to proteasome inhibitors
[108]. Studies using in vivo and in vitro pancreatic cancer
models demonstrated that these cytoprotective beneﬁts were
compromised when employing vorinostat or siRNA against
HDAC 6 (a cytoskeleton- associated HDAC known to be
required for aggresome formation), resulting in endoplasmic
reticulum (ER) stress and synergistic apoptosis [108]. This
was a selective eﬀect since neither aggresome formation by
bortezomibnorapoptosisbybortezomib/vorinostatregimen
was observed in normal human pancreatic epithelial cells or
in murine pancreatic epithelial cells in vivo. These ob-
servations supported earlier work in MM cells using the
speciﬁc HDAC 6 inhibitor, tubacin, which synergized withJournal of Biomedicine and Biotechnology 9
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Figure 3: Combination of HDACi with proteasome inhibitors induces cellular stress. Synergistic apoptosis is observed between HDACi and
three structurally diﬀerent proteasome inhibitors—marizomib, carﬁlzomib, and bortezomib. The cell death observed with this therapeutic
strategy is generally oxidant dependent. Individually both proteasome inhibitors and HDACi generate ROS, either via mitochondrial injury
or by disregulating antioxidant systems as described in the text. When paired, these two compounds dramatically increase oxidative stress,
which leads to apoptosis. High levels of ROS can also cause damage to proteins which can contribute to ER stress. Inhibiting the proteasome
also results in aggregates of conjugated ubiquitin proteins that were originally to be degraded by the proteolytic complex. HDAC 6 mediates
aggresome formation as a cytoprotective measure in the cell. Addition of HDACi disrupts aggresomes, leading to ER stress, which can
stimulate oxidative stress or directly induce apoptosis.
bortezomib to induce lethality [109]. Both oxidative stress
and interfering with aggresome formation leading to induc-
tion of ER stress are important pathways described that are
considered to contribute to the synergy observed between
bortezomib and HDACi. However, since both of these
drugs have many pleiotropic eﬀects, one cannot discard
other mechanisms also being involved. Nevertheless, the
preclinical evidence demonstrating synergy between these
compounds warrants studying this combination in patients.
Indeed, combination therapy between bortezomib and
HDACi is currently being evaluated in numerous clinical
trials (Table 1).
8.2. Marizomib. Marizomib is a clinically relevant naturally
derived proteasome inhibitor that has been shown to block
all three enzymatic activities of the proteasome resulting in
programmed cell death in leukemic, MM, Waldenstrom’s
macroglobulinemia, colorectal, and pancreatic cancer cells
[110–114]. The combination of marizomib and vorinostat
is being evaluated in a phase I clinical trial in patients with
selected advanced malignancies (Table 1). We combined this
irreversible proteasome inhibitor with HDACi (vorinostat
or entinostat) and showed for the ﬁrst time that this
regimen induced synergistic apoptosis in both primary and
cultured acute leukemia cells [115]. Isobologram analysis
indicated that these synergistic eﬀects were stronger than
those achieved with a bortezomib and HDACi combination.
Intracellular superoxide levels were also observed with mari-
zomib/entinostat or vorinostat treatment compared to single
agents in a Jurkat ALL cell line [115]. Work in MM and our
studies in leukemia had previously identiﬁed caspase-8 as an
important regulator of marizomib-induced apoptosis [110,
113]. Furthermore, we had also shown that the cytotoxicity10 Journal of Biomedicine and Biotechnology
observed in leukemia cells with marizomib was oxidant
dependent since an antioxidant prevented apoptosis. Using
a variant of the Jurkat cell line that lacked caspase-8, we con-
ﬁrmed the requirement of this caspase for ROS-generation
by marizomib alone and in combination with HDACi [115].
Interestingly, we also observed that marizomib and HDACi
shared overlapping biochemical eﬀects. Both vorinostat and
e n t i n o s t a tw e r ea b l et od o w n r e g u l a t em R N Ae x p r e s s i o n
levels of beta subunits that contain the proteolytic activities
oftheproteasomeandaccordinglydecreasedtheirenzymatic
eﬀects [115]. We also showed that marizomib was able to
increase histone-H3 expression and acetylation [115]. This
was the ﬁrst report of this epigenetic alteration, usually asso-
ciated with HDAC inhibition, occurring as a consequence
of proteasome inhibition, and it was speciﬁc to marizomib
since bortezomib did not elicit the same eﬀect. Furthermore,
caspase-8 inﬂuenced the acetylation triggered by marizomib,
since the proteasome inhibitor did not inﬂuence the acety-
lation in caspase-8-deﬁcient cells, but this eﬀect was recov-
ered when caspase-8 was re-expressed. Overall, our results
demonstrated that caspase-8 and oxidative stress contribute
to the synergy observed between marizomib and HDACi.
Unlike bortezomib, the novel second-generation proteasome
inhibitor also had the ability to inﬂuence an epigenetic
modiﬁcation, as demonstrated by acetylation of histone
H3, and provided another potential mechanism explaining
why more synergy is observed with marizomib/HDACi
compared to a bortezomib/HDACi regimen. However, a
more recent study suggests that bortezomib may also be
capable of modulating acetylation. In fact, their work with
bortezomib may provide the missing link observed with
marizomib’s caspase-8-dependent acetylation. Kikuchi et al.
report transcriptional downregulation of class I HDACs
by bortezomib, which is mediated by caspase-8-dependent
degradation of transcription factor, SP1 [116]. These data
provides further evidence that proteasome inhibitors share
an overlapping mechanism with HDACi.
8.3. Carﬁlzomib. Formerly known as PR-171, carﬁlzomib
is a newly described irreversible proteasome inhibitor. This
synthetic epoxyketone-based inhibitor is selective to potently
block the chymotrypsin-like activity and is currently in clin-
ical trials for MM and non-Hodgkin’s lymphoma [117].
Compared to bortezomib, carﬁlzomib more potently killed
MM cells and overcame resistance in patient-derived cells
that demonstrated bortezomib resistance in the clinic [118].
Given that bortezomib is able to interact with HDACi to
cause apoptosis, it is plausible that this next-generation pro-
teasome inhibitor can also act synergistically with HDACi.
Studies in diﬀuse large B cell lymphoma (DLBCL) demon-
strated that carﬁlzomib and vorinostat interacted synergis-
tically in DLBCL [119]. Notably, increased JNK activation
contributed to lethality since interference RNA against JNK,
dominant negative JNK, and peptide inhibitors reduced JNK
activation and attenuated carﬁlzomib/HDACi cytotoxicity
[119]. Combination treatment with carﬁlzomib and vorino-
stat also increased DNA damage, apoptosis and reduced
tumor growth in mouse models. This regimen also showed
activity against primary cells and DLBCL cells resistant to
bortezomib [119].
Oxidative stress, ER stress, and JNK activation are com-
mon pathways by which proteasome inhibitors and HDACi
work in concert to enhance lethality in tumor cells. However,
mechanisticstudiesbetweenHDACiandthenext-generation
proteasome inhibitors are identifying new potential mech-
anisms, such as acetylation by marizomib that may also be
involved in triggering cytotoxicity. Given that both HDACi
and proteasome inhibitors inﬂuence numerous cellular
eﬀects, further studies examining their interactions may
reveal additional overlapping mechanisms that have not yet
been identiﬁed as contributing to their synergism. Together,
the preclinical studies between proteasome inhibitors and
the epigenetic modiﬁers, HDACi, have provided substantial
data reinforcing the potential clinical utility of these two
compounds, and results from the current clinical trials are
anxiously being awaited.
9.HDACiandDNA-Damaging Agents
Another combination that may provide synergistic beneﬁts
to cancer patients is that of HDACi with agents that cause
DNA damage. HDACi have been widely shown to lead to
radiosensitization in cell lines and in some mouse mod-
els,andtherearemanypossibleexplanationsfortheseeffects.
One idea is that histone deacetylase inhibitors are capable
of disrupting the DNA damage response, so their addition
prolongs the eﬀects of DNA-damaging agents. This idea is
supported by the fact that many researchers have observed
prolonged γ-H2AX, which indicates the presence of DNA
double-strand breaks, when HDACi are added to treatment
with DNA-damaging agents such as radiation [120, 121].
Another possible explanation is that treatment with HDACi
“loosens” the chromatin conformation, making the DNA
more accessible to damaging agents. While it is diﬃcult
to provide concrete evidence for this idea, it is deﬁnitely
clear that chromatin structure is an important consideration
for the cell’s ability to sense and repair double-strand
breaks [122]. A ﬁnal idea for why HDACi are eﬀective
radiosensitizersdrawsfromtheabilityofHDACitomodulate
gene expression, so they may act by changing expression
of genes speciﬁcally involved in DNA damage responses or
survival [123]. This hypothesis is supported by previous
reports that HDACi lead to increases in several well-known
proapoptotic proteins, such as Bim and Bmf [123]. To test
these hypotheses, many HDACi have been combined with
DNA-damaging agents such as radiation and chemothera-
peutic agents.
9.1. Radiation. Several HDACi have shown eﬃcacy as radi-
osensitizing agents when combined with ionizing radiation
(IR). Many diﬀerent HDACi have been tested in a wide panel
of diﬀerent cell lines. Some models where HDACi have been
shown to radiosensitize cell lines include the use of valproic
acid in colon cancer [120]a n db r a i nt u m o r s[ 124], panobi-
nostat (LBH589) in non small cell lung cancer [121], TSA inJournal of Biomedicine and Biotechnology 11
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Figure 4: Several therapeutic combinations with HDACi show promising results. Some agents which have been shown to cause synergistic
cell death when combined with HDACi include (1) DNA-damaging agents, such as radiation and many chemotherapies, which may take
advantage of the increased access to DNA, provided by the “loose” chromatin arrangement after HDACi treatment, to cause increased
DNA damage, (2) modulators of methylation, such as histone demethylase inhibitors and DNA methyltransferase inhibitors, which have
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increase cellular stress and lead to production of reactive oxygen species, can synergize with HDACi, and (4) ROS-generating agents, such as
adaphostin, work with HDACi to amplify ROS production, adding to the already increased ROS levels in cancer cells until toxic levels lead
to cell death.
nonsmallcelllung cancer[125]andmedulloblastoma[126],
FK228 in gastric and colorectal adenocarcinoma [127], PCI-
24781 in cervical and colon carcinoma [128], and vorinostat
in medulloblastoma [126] and melanoma [129]. There have
also been studies in mouse models that indicate that this is
an eﬀective combination. Camphausen et al. have found that
the treatment of DU145 prostate carcinoma xenografts with
entinostat radiosensitized them in a manner that correlated
with their ability to cause hyperacetylation in these animals
[130]. Clearly, the evidence that HDACi can successfully
sensitize cells to radiation is quickly accumulating.
Interestingly, Kim et al. have shown that inhibiting some
c l a s s e so fH D A C ss e e m st ob em o r ee ﬀective than inhibiting
others. This is an important observation since each HDACi
has a diﬀerent inhibition proﬁle. This study showed that the
most eﬀective inhibitors were TSA (inhibits class I and II
HDACs) followed by SK7041 (inhibitor of class I), while the
least eﬀective inhibitor was a suppressor of class III HDACs
(splitomicin) [131].
9.2. Topoisomerase II Inhibitors. Many of the same concepts
mentioned previously can be applied to combinations of
HDACi with various chemotherapies that induce DNA
damage. This line of thought led investigators to combine
HDACiwithtopoisomeraseII(TopoII)inhibitors.Inastudy
where several cancer cell lines were treated with either
vorinostat or TSA, then subsequently treated with a Topo II
inhibitor such as cisplatin or 5-ﬂuorouracil, the combination
was shown to be more eﬀective at causing cell death than
the chemotherapeutics alone. The investigators in this study
also tried to switch the drug order, treating with the chem-
otherapy ﬁrst and the HDACi second. This particular
administration did not oﬀer any sensitivity advantage over
using the chemotherapy as a single agent. The authors pro-
posed that this was evidence that the eﬀectiveness of the
combination stems from the ability of HDACi to allow
increased access to DNA to the Topo II enzymes, which are
then “locked” onto the DNA by the subsequent treatment
with Topo II inhibitors, leading to increased DNA damage
[132].
9.3.Temozolomide. Temozolomideisanalkylatingagentthat
is commonly combined with radiation for the treatment of
gliomas [133]. A study in a glioblastoma cell line showed
that the best response may be seen when the HDACi AN-9
was combined with both radiation and temozolomide [134].
Observations of the eﬀectiveness of temozolomide with
HDACi have led to several clinical trials, mainly for gliomas
(http://www.clinicaltrials.gov/).Thoughtrialsaremostlystill
in early stages, preliminary results indicate that the side12 Journal of Biomedicine and Biotechnology
eﬀectsofcombinationssuchasvorinostatandtemozolomide
are fairly well tolerated [135]. A few of the combinations
of HDACi with temozolomide now in clinical trials can be
found in Table 1.
Overall, studies examining the interaction between
HDACi and DNA-damaging agents, including radiation or
chemotherapeutics, are providing the rationale to combine
to these anticancer therapies for clinical utility.
10. Conclusions
Inhibitors of histone deacetylases are promising compounds
for the treatment of cancer, and as a result, the ﬁrst
HDACi was approved for CTCL. Many of the cellular out-
comes of HDAC inhibition are caused by changes in gene
expression that inﬂuence growth inhibition, diﬀerentiation,
and apoptosis of malignant cells. However, due to their
limited activity in speciﬁc cancer types as single agents,
the future of HDACi may reside in combination therapies.
Here, we reviewed potential candidates, such as inhibitors
of DNA methyltransferases and histone demethylases, ROS-
generating compounds, proteasome inhibitors, and DNA-
damaging agents, that have demonstrated enhanced eﬃcacy
when combined with HDACi and may provide a therapeutic
advantageintheclinic(Figure 4).Thesecombinationstudies
oﬀer the rationale to explore these therapies and provide
the molecular framework for better therapeutic strategies.
Preclinical data suggests that combination treatments may
lead to better eﬃcacy and utility of HDACi in the clinic.
However, the eﬀects of these combinations on dose-limiting
toxicities have not thoroughly been evaluated. Combina-
tion studies will oﬀer the opportunity to use lower doses
and reduce dose-limiting toxicities, which include fatigue,
vomiting, nausea, and diarrhea, among others, that have
been observed with HDACi as single agents [39, 45, 50].
While there could be concerns that using combinations of
agents may result in increased toxicity, the preliminary data
from current clinical trials show promise that combinations
can be safe and tolerated. Early data from phase I studies
in refractory or relapsed multiple myeloma patients using
HDACi/bortezomib regimens indicate similar adverse eﬀects
associated with HDACi but no dose-limiting toxicities
have yet to be reported [136]. In another ongoing study
evaluating vorinostat with 5-azacitidine in a phase I trial
in myelodysplastic syndrome (n = 20) and acute myeloid
leukemias (n = 8) patients, preliminary results demonstrate
complete response in 43% of participants, while observing
grade 1-2 toxicities (fatigue and anorexia) [137]. There
are some regimens that are showing response but present
toxicities [138]; however, these combinations are currently
being tested in phase I trials where the main objective
is to try to determine the ideal doses that will improve
eﬃcacy with minimal toxicities to patients. Additionally,
another important factor to consider is that most partici-
pants enrolled in clinical trials have already been exposed
to various anticancer agents and chemotherapeutics and
already present preexisting conditions that perhaps inﬂuence
their sensitivity to dose-limiting toxicities. It will not be until
these ongoing trials are complete that we can make a de-
ﬁnitive conclusion whether these combination approaches
are suitable alternatives for cancer patients. While HDACi
are providing anticancer beneﬁts, we cannot exclude that the
precise mode of action of how HDACi are killing cancer cells
is still unknown. Thus, further understanding of this process
may oﬀer insights into how best to use these inhibitors and
design better treatment regimens. Much of the work to date
focuses on examining gene alterations as a consequence of
HDAC inhibition due to acetylation of histones; however,
new exciting data seems to suggest that we have to take into
consideration other mechanisms. Interestingly, hyperacety-
lationofnonhistoneproteinsislinkedtotheHDACieﬀecton
cancer cells [139]. Transcription factors such as p53, HIF-1,
and E2F1, signaling molecule Smad 7, the chaperone protein
Hsp90,andthestructuralproteintubulinareallsubstratesof
HDACs. A recent study examining the acetylome identiﬁed
numerous target proteins that can be acetylated. A mass
spectrometry study identiﬁed over 3,500 lysine acetylation
sites in 1,750 proteins [51]. Importantly, they observed an
increase in the acetylation of nonhistone proteins in cells
treated with HDACi, entinostat and vorinostat. Surprisingly,
these HDACi only increase acetylation on 10% of all acet-
ylation sites suggesting that their eﬀects are very selective.
As expected, diﬀerences in acetylation of substrates were
observed between both HDACi. For example, vorinostat was
a more potent inducer of histone acetylation and of DNA
double-strand breaks, as demonstrated by an increase in γ-
H2AX. The nonhistone substrate, Hsp90, was also highly
acetylated with vorinostat but not with entinostat. On the
other hand, the tumor suppressor p53 was acetylated to a
higher degree with entinostat whereas vorinostat did not
inﬂuence the acetylation of this protein. These diﬀerences
probably reﬂect the ability of these compounds to target
diﬀerent HDACs. The identiﬁcation of the acetylome oﬀers
a snapshot of the diﬀerent proteins that may be inﬂuenced
by acetylation and therefore by HDACi. These types of
experiments that attempt to elucidate the great spectrum
of protein acetylation [51] have revealed new targets and
unknown potential mechanisms by which HDACi may work
as an eﬀective therapy for cancer. Studies like these can be
mined to identify molecular end points that can be targeted
with more eﬃcacious HDACi-combination therapies.
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